Molecular Partners AG
MP0726
ovarian cancer
Resolved
7days ago
Phase 1 readout · ~ Jun 30, 2026 estimated
What's at stake
Phase 1 trial results for MP0726 in ovarian cancer are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 13h ago
“preclinical data on MP0726 at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in June 2025, highlighting the program’s potential to overcome challenges faced by other MSLN-targeted therapies.”